Full Press Release Details
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.
| 11th Annual SVB Leerink Global Healthcare Conference | |||
| Date: | Wednesday, February 16 th , 2022 | ||
| Time: | 11:20am Eastern Time | ||
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab, formerly referred to as IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Director, Investor Relations & Strategy